Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Flatiron Health Real-World Data Support FDA Approval of New Dosing Regimen for ERBITUX® (Cetuximab)
Details : This alternate dosing regimen to the previously approved weekly dosing regimen allows ERBITUX infusions to be scheduled alongside other biweekly treatments, significantly reducing the frequency of patient visits to an infusion center.
Brand Name : Erbitux
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 20, 2021
LOOKING FOR A SUPPLIER?
Reset All
